Stock Movers cover image

BioMarin Rises, FedEx Drops and Nike Sinks on Sales Warning

Stock Movers

00:00

BioMarin to buy Amicus for rare-disease boost

Scarlet Fu reports BioMarin's agreement to buy Amicus for about $4.8 billion, expanding its rare-disease treatment portfolio.

Play episode from 03:17
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app